All In Biotech

NDA 019888 · Almatica

Zestoretic

Hydrochlorothiazide, Lisinopril · Oral · Thiazide Diuretic

Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Jul 20, 1989

Approved uses

2

Original approval plus efficacy supplements

Registered trials

450

138 Phase 3, 14 recruiting

FAERS reports

10,267

6,201 serious, 596 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue ZESTORETIC as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity.

What it is approved for

From the label in effect Mar 31, 2025.

INDICATIONS AND USAGE ZESTORETIC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 18, 1993 Supplement 11 · Efficacy
  • Jul 20, 1989 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • ZESTORETIC · HYDROCHLOROTHIAZIDE 12.5MG; LISINOPRIL 10MG · TABLET, ORAL · Prescription · TE AB
  • ZESTORETIC · HYDROCHLOROTHIAZIDE 12.5MG; LISINOPRIL 20MG · TABLET, ORAL · Prescription · TE AB
  • ZESTORETIC · HYDROCHLOROTHIAZIDE 25MG; LISINOPRIL 20MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.

All 450 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea692
  • fatigue684
  • diarrhoea618
  • drug ineffective577
  • pain505
  • dizziness498
  • dyspnoea444
  • headache438
  • asthenia372
  • vomiting357
  • cough354
  • arthralgia341

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004174
2005178
2006210
2007230
2008312
2009501
2010786
2011771
2012726
2013175
2014440
2015833
2016581
2017430
2018553
2019474
2020530
2021449
2022417
2023410
2024355
2025440
2026292

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zestoretic (Lisinopril/Hydrochlorothiazide)

2024 spending

$696K

Beneficiaries

183

659 claims

Per beneficiary

$3,805

$12.52 per unit

View as table
YearSpending
2020$1,306,300
2021$1,175,166
2022$1,044,872
2023$882,756
2024$696,348

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,366 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.